| Bioactivity | Danirixin is a selective, and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8. | ||||||||||||
| Invitro | Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine[1]. | ||||||||||||
| Name | Danirixin | ||||||||||||
| CAS | 954126-98-8 | ||||||||||||
| Formula | C19H21ClFN3O4S | ||||||||||||
| Molar Mass | 441.90 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Miller BE, et al. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist?--in healthy adult subjects. BMC Pharmacol Toxicol. 2015 Jun 20;16:18. |